United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News GSK to acquire vaccine developer Affinivax in deal worth up to $3.3bn GlaxoSmithKline (GSK) has agreed to acquire Affinivax, a Boston-based clinical-stage vaccine developer, in a deal worth up to… bySrinathJune 1, 2022
